ThromboGenics Signs Potential $494M Ex-U.S. Ocriplasmin Deal

Moran, Nuala
March 2012
BioWorld Today;3/19/2012, Vol. 23 Issue 43, p1
The article reports on ThromboGenics NV initially getting paid 75 million euros by Alcon Inc. The royalty given is for the exclusive rights of ocriplasmin in the U.S. ThromboGenics will receive a further amount of 90 million euros for the launching and approval of the said recombinant form of human plasmin in Europe.


Related Articles

  • ThromboGenics Banks $59M Milestone on EU Approval. Sheridan, Cormac // BioWorld International;3/20/2013, Vol. 18 Issue 12, p3 

    The article uncovers the financial conditions of ThromboGenics NV following the 58.8 million dollars payment from Alcon Inc. for commercializing Jetrea, also known as ocriplasmin, in the European Union (EU). It is noted that the EU approved Jetrea as treatment for patients with vitreomacular...

  • Novartis' Alcon Gains ex-US Rights to ThromboGenics' Ocriplasmin. Cartwright, Heather // PharmaDeals Review;2012, Vol. 2012 Issue 3, p46 

    Alcon, Novartis' ophthalmic division, has gained exclusive ex-US rights to commercialise ThromboGenics' ocriplasmin for symptomatic vitreomacular adhesion in a deal potentially worth more than €375 M (US$489 M), including €75 M (US$98 M) upfront. Ocriplasmin is under regulatory...

  • Alcon to pay $1.5M plus royalty fees for Irede GreenTip rights.  // Medical Device Daily;11/16/2011, Vol. 15 Issue 220, p2 

    The article reports on a license and distributional deal between U.S. medical equipment developers Iridex and Alcon which focuses on the royalty fees of 1.5 million U.S. dollars paid by Alcon for the distribution of Iridex Green Tip Soft Tip Cannula family of products in the country.

  • New size taking flight.  // Optometry Today;6/18/2010, Vol. 50 Issue 12, p22 

    The article reports on the launch of Opti-Free RepleniSH Flight Pack by Alcon Inc. in Great Britain.

  • ThromboGenics Procures License For Heart Drug.  // Bioworld Week;10/8/2007, Vol. 15 Issue 41, p5 

    The article reports on the terms of the ThromboGenics NV's licensing contract with Rhein Minapharm SAE for preclinical THR-174. The deal could promote the next-generation thrombolytic treatment for heart attacks in developing countries. The company will acquire milestone payments and royalties...

  • ThromboGenics Extends Runway with $103.2M Raise. Powers, Marie // BioWorld Today;3/30/2012, Vol. 23 Issue 62, p1 

    The article reports on the 77.8 million euros in funding raised by ThromboGenics NV via a private placement deal with both domestic and international investors. The cash position of Belgium-based ThromboGenics has been boosted to 230 million euros as a result of the deal. ThromboGenics Chief...

  • ThromboGenics Signs Potential $494M Ex-U.S. Ocriplasmin Deal. Moran, Nuala // BioWorld International;3/21/2012, Vol. 17 Issue 12, p1 

    The article reports on the 75 million euros in up front fees to be received by ThromboGenics NV under a royalties deal with eye care specialist Alcon Inc. for the ex-U.S. rights to ocriplasmin. A further 90 million euros will be received by ThromboGenics once the vitreous macular adhesion (VMA)...

  • ThromboGenics, Alcon Get European Nod for Jetrea. Sheridan, Cormac // BioWorld Today;1/22/2013, Vol. 24 Issue 14, p1 

    The article reports that ThromboGenics NV and the Alcon unit of Novartis AG attained a positive opinion from the European Medicines Agency's Committee for Medicinal Products for Human Use (CHMP) for Jetrea. It tells that Jetrea is a treatment for vitreous macular traction. It says that the move...

  • ThromboGenics Banks $59M Milestone on EU Approval. Sheridan, Cormac // BioWorld Today;3/18/2013, Vol. 24 Issue 51, p1 

    The article reports that Leuven, Belgium-based ThromboGenics NV will earn 58.8 million dollars from partner firm Alcon after the European Union (EU) issued approval on the drug Jetrea developed for the treatment of vitreomacular traction. The drug previously earned approval from the European...


Read the Article


Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics